ALL BCOP QUESTIONS AND ANSWERS.

ALL BCOP QUESTIONS AND ANSWERS.
melanoma - Stage I or II correct answers surgery

melanoma - Stage III correct answers nivolumab, ipilumumab

melanoma - BRAF positive Stage III correct answers dabrafenib + trametinib

melanoma - BRAF positive Stage IV, aggressive, bulky, symptomatic correct answers dabrafenib
+ trametinib, vemurafenib + cobimetinib

melanoma - Unresectable stage III with in-transit lesions correct answers Talimogene
Laherparepvec (T-VEC)

melanoma - Stage IV correct answers nivolumab, pembrolizumab

melanoma - BRAF positive Stage IV minimally symptomatic correct answers nivolumab,
pembrolizumab, nivolumab + ipilimumab (Stage IV immunotherapy)

metastatic basal cell carcinoma correct answers vismodegib, sonidegib

CLL - Age < 65 without significant comorbidies without del 17p/TP53 correct answers FCR,
ibrutinib, bendamustine with or without cd20 MoAb

CLL - Age < 65 without significant comorbidities without del 17p/TP53 relapse/refractory
correct answers ibrutinib, idelalisib + R, venetoclax with or without R

CLL - Age < 65 without significant comorbidies without del 17p/TP53 maintenance correct
answers consider lenalidomide for high risk

CLL - Age > 65 or younger patients with significant comorbidities without del 17p/TP53 correct
answers Obinutuzumab + chlorambucil, ibrutinib, ofatumumab + chlorambucil, rituxan +
chlorambucil, bendamustine with or without R

CLL - Age > 65 or younger patients with significant comorbidities without del 17p/TP53
maintenance correct answers consider lenalidomide for high risk

CLL - Age > 65 or younger patients with significant comorbidities without del 17p/TP53
relapse/refractory correct answers ibrutinib, idelalisib + R, venetoclax with or without R

CLL - Frail patients with significant comorbidities without del 17p/TP53 correct answers
Obinutuzumab + chlorambucil, ibrutinib, ofatumumab + chlorambucil, rituxan + chlorambucil

CLL - Frail patients with significant comorbidities without del 17p/TP53 maintenance correct
answers consider lenalidomide for high risk

,Frail patients with significant comorbidities without del 17p/TP53 relapsed/refractory correct
answers ibrutinib, idelalisib + R, venetoclax with or without R

CLL - With del 17p/TP53 correct answers ibrutinib**, HDMP + rituxan, obinutuzumab,
alemtuzumab with or without rituxan

CLL - With del 17p/TP53 relapsed/refractory correct answers ibrutinib, idelalisib + R,
venetoclax with or without R

CLL - With del 17p/TP53 maintenance correct answers consider lenalidomide for high risk

NSCLC stage IA correct answers surgery

NSCLC stage IB correct answers surgery

NSCLC stage IIA correct answers surgery followed by cisplatin doublet

NSCLC stage IIB correct answers surgery followed by cisplatin doublet

NSCLC stage IIIA correct answers surgery followed by cisplatin doublet

NSCLC stage IIIB correct answers surgery followed by cisplatin doublet + XRT

NSCLC stage III consolidation correct answers durvalumab

NSCLC stage IV PD-LI >50% correct answers pembrolizumab

NSCLC stage IV SCC correct answers cisplatin/gemcitabine

NSCLC stage IV adenocarcinoma no driver mutation, no PD-L1 expression correct answers
platinum based doublet or carbo/pem/pem

NSCLC stage IV nonsquamous EGFR positive correct answers erlotinib, afatinib, gefitinib,
osimertinib (2a rec)

NSCLC stage IV nonsquamous T790M mutation correct answers osimertinib

NSCLC stage IV nonsquamous EML4-ALK positive correct answers alectinib (preferred),
crizotinib, ceritinib

NSCLC stage IV nonsquamous ROS-1 positive correct answers crizotinib, ceritinib

NSCLC stage IV nonsquamous BRAF V600E positive correct answers dabrafenib+trametinib

NSCLC continuation maintenance correct answers pemetrexed (nonsquamous),
pemetrexed/avastin, gemzar

, NSCLC switch maintenance correct answers pemetrexed (nonsquamous), docetaxel

NSCLC stage IV nonsquamous EGFR positive second line correct answers erlotinib, gefitinib,
afatanib

NSCLC stage IV nonsquamous EGFR positive third line correct answers chemo preferred over
immunotherapy

NSCLC stage IV nonsquamous ALK positive second line correct answers ceritinib, alectinib,
brigatinib

NSCLC stage IV nonsquamous ALK positive third line correct answers chemo preferred over
immunotherapy

NSCLC stage IV second line after progression on platinum based chemo (immunotherapy)
correct answers nivolumab, pembrolizumab (PD-L1 >1%), atezolizumab

NSCLC stage IV second line after progression on platinum based chemo (chemo) correct
answers docetaxel, pemetrexed, ramucirumab+docetaxel

Stage IV mesothelioma correct answers Pemetrexed/cisplatin (category 1),
pemetrexed/cisplatin/avastin (category 2)

Stage 1A or stage 1B (grade 1 and 2) ovarian correct answers surgical staging + observation.
taxane/carbo for 3-6 cycles if grade 2

Stage 1A or 1B (grade 3) and Stage 1C (grade 1, 2, 3) ovarian correct answers surgical staging +
taxane/carbo 3-6 cycles

Stage 2 ovarian correct answers surgical staging + taxane plus platinum IV or IP (in <1cm
optimally debulked, category 2a) for 6 cycles

Stage 3 ovarian correct answers surgical staging + taxane/carbo, carbo/doxil, cisplatin/taxol, IP
chemo (category 1)

Stage 4 ovarian correct answers surgical staging + taxane/carbo, carbo/doxil, cisplatin/taxol

Platinum sensitive recurrent disease ovarian correct answers disease free for >6 months -
platinum based chemo (carbo/taxol, doxil/carbo category 1)

Platinum sensitive recurrent disease ovarian w/ neuropathy correct answers gemzar/carbo or
gemzar/cisplatin reverses platinum resistance

Platinum sensitive recurrent disease ovarian but cannot tolerate combination chemo correct
answers cisplatin, carboplatin